Heather Neu is a highly motivated and innovative Principal Scientist at Bristol Myers Squibb, where she leverages her extensive expertise in analytical, inorganic, organic, and biological chemistry to drive impactful research and development initiatives. With nine years of experience in the pharmaceutical industry, Heather plays...
Heather Neu is a highly motivated and innovative Principal Scientist at Bristol Myers Squibb, where she leverages her extensive expertise in analytical, inorganic, organic, and biological chemistry to drive impactful research and development initiatives. With nine years of experience in the pharmaceutical industry, Heather plays a pivotal role as the analytical lead and subject matter expert (SME) for nine critical projects that span from initial Investigational New Drug (IND) applications through to registration. Her work primarily focuses on the development of small molecules and Antibody Drug Conjugates (ADCs), where she is instrumental in the characterization of active pharmaceutical ingredients (APIs), starting materials, and intermediates.
In her current role, Heather has made significant contributions to drug substance process development by providing robust support in method development, optimization, and transfer. Her proficiency in analytical methods development, particularly in mass spectrometry and nuclear magnetic resonance (NMR), enables her to deliver precise and reliable data that informs key decision-making processes. Additionally, Heather excels in manufacturing process improvement and deviation management, ensuring that projects adhere to stringent timelines and quality standards.
Beyond her technical acumen, Heather is deeply committed to fostering a collaborative and growth-oriented environment. She actively mentors researchers of diverse skill levels, guiding them in their professional development and empowering them to achieve project success. Her dedication to innovation and excellence not only drives her projects forward but also contributes to the overall mission of Bristol Myers Squibb to discover and deliver transformative medicines to patients in need.
